Back to News
Market Impact: 0.42
Daiichi Sankyo Gets Japan Approval For Enhertu, Datroway In First-Line Metastatic Breast Cancer
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Japan's Ministry of Health, Labour and Welfare approved Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan) for new first-line metastatic breast-cancer indications. The approvals expand the addressable use of two key oncology drugs and should support Daiichi Sankyo's growth outlook in Japan.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
More News
- Apple's quarter is not perfect. But with enough to like, we raised our price target
- California’s Bay Area debates data centres ahead of US midterm elections
- ‘Fastest entertainment property in history’: GTA VI arrives to test a thin November box office
- In one of the largest deals in tech history, Marvell buys Lumentum for $115B
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- ‘Going hungry’: Garment workers in Bangladesh say wages barely cover needs